{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:32:52Z","timestamp":1791999172372,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ebiom.2023.104785","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T15:13:16Z","timestamp":1693840396000},"page":"104785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7172-8424","authenticated-orcid":false,"given":"Christina V.","family":"Konrad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2770-1942","authenticated-orcid":false,"given":"Emma F.","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-0259","authenticated-orcid":false,"given":"Jesper D.","family":"Gunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Monrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Holleufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1159-066X","authenticated-orcid":false,"given":"Rune","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars J.","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole S.","family":"S\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane H.","family":"Schleimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7020-5173","authenticated-orcid":false,"given":"Martin","family":"Tolstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"95","key":"10.1016\/j.ebiom.2023.104785_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"177","key":"10.1016\/j.ebiom.2023.104785_bib2","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.ebiom.2023.104785_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104785_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.ebiom.2023.104785_bib5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ebiom.2023.104785_bib6","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"issue":"5891","key":"10.1016\/j.ebiom.2023.104785_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104785_bib8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ebiom.2023.104785_bib9","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104785_bib10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol Ther"},{"issue":"132","key":"10.1016\/j.ebiom.2023.104785_bib11","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104785_bib12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A\u00a0phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104785_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4\u03b6 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus\u2013infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"issue":"504","key":"10.1016\/j.ebiom.2023.104785_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in\u00a0vitro antiviral activity and potent in\u00a0vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Anthony-Gonda","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104785_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006613","article-title":"Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor","volume":"13","author":"Leibman","year":"2017","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104785_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T\u00a0cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104785_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104785_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/imr.12823","article-title":"T-cell exhaustion in HIV infection","volume":"292","author":"Fenwick","year":"2019","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104785_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nm0396-338","article-title":"Endocytosis of major histocompatibility complex class I molecules is induced by the HIV\u20131 Nef protein","volume":"2","author":"Schwartz","year":"1996","journal-title":"Nat Med"},{"issue":"6665","key":"10.1016\/j.ebiom.2023.104785_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/34929","article-title":"HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes","volume":"391","author":"Collins","year":"1998","journal-title":"Nature"},{"issue":"469","key":"10.1016\/j.ebiom.2023.104785_bib21","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"issue":"44","key":"10.1016\/j.ebiom.2023.104785_bib22","doi-asserted-by":"crossref","first-page":"26562","DOI":"10.1074\/jbc.M115.676130","article-title":"Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy","volume":"290","author":"Chang","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104785_bib23","first-page":"641","article-title":"Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6","volume":"2","author":"Maeurer","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104785_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104785_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.ebiom.2023.104785_bib26","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104785_bib27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1054\/bjoc.1999.1042","article-title":"Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I\/peptide complexes","volume":"82","author":"Ogg","year":"2000","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104785_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2326-6066.CIR-15-0037","article-title":"Committing cytomegalovirus-specific CD8 T cells to eliminate tumor cells by bifunctional major histocompatibility class I antibody fusion molecules","volume":"3","author":"Schmittnaegel","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104785_bib29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/1535-7163.MCT-14-0467","article-title":"Recruitment of oligoclonal viral-specific T cells to kill human tumor cells using single-chain antibody-peptide-HLA fusion molecules","volume":"14","author":"Noy","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104785_bib30","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1002\/1521-4141(200011)30:11<3165::AID-IMMU3165>3.0.CO;2-R","article-title":"Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes","volume":"30","author":"Robert","year":"2000","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104785_bib31","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.4049\/jimmunol.169.6.2988","article-title":"Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes","volume":"169","author":"Lev","year":"2002","journal-title":"J\u00a0Immunol"},{"issue":"42","key":"10.1016\/j.ebiom.2023.104785_bib32","doi-asserted-by":"crossref","first-page":"68503","DOI":"10.18632\/oncotarget.11785","article-title":"Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells","volume":"7","author":"Sch\u00fctz","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104785_bib33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/sj.leu.2404185","article-title":"Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA\/CMV complexes","volume":"20","author":"Mous","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104785_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ijc.22168","article-title":"Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in\u00a0vitro and in\u00a0vivo","volume":"120","author":"Novak","year":"2007","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104785_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1834818","article-title":"Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in\u00a0vivo","volume":"12","author":"Fischer","year":"2020","journal-title":"MAbs"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104785_bib36","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104785_bib37","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201949351","article-title":"Anti- HIV -1 antibodies trigger non-lytic complement deposition on infected cells","volume":"21","author":"Dufloo","year":"2020","journal-title":"EMBO Rep"},{"issue":"47","key":"10.1016\/j.ebiom.2023.104785_bib38","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.ebiom.2023.104785_bib39","doi-asserted-by":"crossref","first-page":"13852","DOI":"10.1128\/JVI.00904-07","article-title":"Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses","volume":"81","author":"M\u00fcnch","year":"2007","journal-title":"J\u00a0Virol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104785_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine\u2014how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ebiom.2023.104785_bib41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J\u00a0Clin Virol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104785_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr Infect Dis Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104785_bib43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/imr.12099","article-title":"Immunity to viruses: learning from successful human vaccines","volume":"255","author":"Pulendran","year":"2013","journal-title":"Immunol Rev"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104785_bib44","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104785_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-00798-1","article-title":"Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination","volume":"7","author":"Kongsgaard","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104785_bib46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-immunol-030409-101253","article-title":"On the composition of the preimmune repertoire of T cells specific for peptide\u2013major histocompatibility complex ligands","volume":"28","author":"Jenkins","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"26","key":"10.1016\/j.ebiom.2023.104785_bib47","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.2634931100","article-title":"Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104785_bib48","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/JVI.76.11.5315-5325.2002","article-title":"Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120\/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus","volume":"76","author":"Chertova","year":"2002","journal-title":"J\u00a0Virol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104785_bib49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/2051013613498954","article-title":"Advances and controversies in yellow fever vaccination","volume":"1","author":"Jonker","year":"2013","journal-title":"Ther Adv Vaccines"},{"issue":"22","key":"10.1016\/j.ebiom.2023.104785_bib50","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"issue":"1-2","key":"10.1016\/j.ebiom.2023.104785_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jviromet.2008.03.002","article-title":"Pressure-inactivated yellow fever 17DD virus: implications for vaccine development","volume":"150","author":"Gaspar","year":"2008","journal-title":"J\u00a0Virol Methods"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104785_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024505","article-title":"Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever","volume":"6","author":"Sch\u00e4fer","year":"2011","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.ebiom.2023.104785_bib53","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423003511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423003511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:23:49Z","timestamp":1762457029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423003511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":53,"alternative-id":["S2352396423003511"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104785","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104785"}}